Understanding APC - malecare.org

Duration of Response to Androgen Deprivation Therapy (ADT) and Efficacy of Secondary ADT, Docetaxel and Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

Men who become castrate resistant in less than 12 months from starting androgen deprivation therapy (ADT) were found to have poor efficacy with a 2nd line of ADT. However, the development of early castrate resistance did not impair the benefit of any of the docetaxel based chemotherapy. Researchers examined the records of 132 consecutive men [...]

By Malecare|2017-10-19T10:48:30-04:00March 21st, 2014|2nd line hormone therapy, Advanced Prostate Cancer, Cabazitaxel, Drugs & Treatments, General Information, Hormone Therapy, Research, Uncategorized, Understanding APC|0 Comments

Tri-weekly Docetaxel Versus Bi-weekly Docetaxel as a Treatment for Advanced Castration Resistant Prostate Cancer: Quality of Life Analysis

Administering chemotherapy using docetaxel (taxotere or T) on a bi-weekly basis with prednisone improved progression free survival and overall survival when compared with the standard tri-weekly schedule for men with advanced castration resistant prostate cancer (CRPC) (Lancet Oncol. 2013;14:117-124). However, quality of life (QoL) differences have not been evaluated. In a trial to evaluate the [...]

By Malecare|2017-10-19T10:48:30-04:00March 20th, 2014|Advanced Prostate Cancer, Chemo Therapy, Clinical Trials, Clinical Trials, Drugs & Treatments, Uncategorized, Understanding APC|2 Comments

Toxicity Analysis of Lymph Node Irradiation for Men with Prostate Cancer Treated with IMRT

The standard of treatment for men who have a localized recurrence in lymph nodes (LN) after surgery is intensity modulated radiation therapy (IMRT) as well as with men who have high-risk prostate cancer which includes cancer in both the prostate and seminal vesicles (SV). As with all treatments the use of IMRT comes with many [...]

By Malecare|2017-10-19T10:48:30-04:00March 17th, 2014|adjuvant therapy, Advanced Prostate Cancer, Drugs & Treatments, Radiotherapy, Research, salvage therapy, Uncategorized, Understanding APC|1 Comment

More Issues Raised About Cross-Resistance Between Abiraterone and Enzalutamide

Some of my posts over the last week or two have discussed the issue of the development of cross-resistance of two of our newest treatments for advanced prostate cancer. These drugs are abiraterone (Zytiga) and enzalutamide (Xtandi). Currently, both of them are approved for use after a man has failed chemotherapy with docetaxel. In addition, [...]

By Malecare|2017-10-19T10:48:30-04:00March 13th, 2014|abiraterone acetate, Advanced Prostate Cancer, Cross Resistance, enzalutamide, Uncategorized, Understanding APC, Xtandi, Zytiga|0 Comments

Markers for Predicting Clinical Responses to Sipuleucel-T (Provenge) in Castrate Resistant Prostate Cancer

Sipuleucel-T (Provenge) has shown in clinical trials that it prolongs overall survival (OS) in asymptomatic or minimally symptomatic men with castrate resistant prostate cancer (CRPC). Unlike many other treatments for men with CRPC there are not any reliable biomarkers to show that it is working for any individual. There is also a lack of markers [...]

By Malecare|2017-10-19T10:48:31-04:00March 12th, 2014|Advanced Prostate Cancer, biomarkers, Drugs & Treatments, Provenge, Uncategorized, Understanding APC, vaccines|0 Comments